Micafungina Teva (Micafungin)

Micafungin blocks the fungal enzyme β‑(1,3)‑D‑glucan synthase, preventing synthesis of β‑(1,3)‑D‑glucan, an essential structural component of the fungal cell wall. This disruption weakens the wall, causing osmotic instability and cell death while sparing human cells that lack this polymer.

The prescribed dose of Micafungina Teva is individualized by the treating physician based on the specific indication, patient weight, renal and hepatic function, and severity of infection. Dosing regimens are outlined in the product label and should not be altered without medical guidance.

Safety data for micafungin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and the decision to use it should be based on a risk‑benefit assessment by the prescriber. Breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Micafungina Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Micafungina Teva belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind to membrane sterols. Echinocandins generally have a favorable safety profile, limited drug‑drug interactions, and are fungicidal against most Candida species, making them a preferred option for certain invasive infections.

Micafungina Teva should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold‑chain throughout to preserve stability and potency.

Micafungina Teva is supplied as a sterile powder for reconstitution and is administered by intravenous infusion. The reconstituted solution is infused over a period specified by the prescribing information, typically 30‑60 minutes, under aseptic conditions in a clinical setting.

Serious adverse events include severe hepatic failure, anaphylactic or severe hypersensitivity reactions, and rare skin disorders such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt recognition and discontinuation of therapy are essential if any of these reactions occur.

Patients with a known hypersensitivity to micafungin or any component of the formulation should avoid its use. Caution is also advised for individuals with severe hepatic impairment, and the drug should be used only when the potential benefit outweighs the risk in such cases.